Abirapro 250mg Tablet

Abirapro 250mg Tablet is an anti-cancer drug which contains Abiraterone acetate and is mainly used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a form of drug known as an androgen biosynthesis inhibitor that prevents the production of androgens (male hormones such as testosterone) that can promote the growth of prostate cancer cells.

Uses of Abirapro 250mg Tablet

• Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC)

How does the Abirapro 250mg Tablet work?

It inhibits the CYP17A1 enzyme which is important in the production of androgens (testosterone) in the adrenal glands, testes and prostate tumour tissues. This blocks the enzyme and greatly reduces androgen levels. Since androgens are needed for prostate cancer cells to grow, reducing their levels helps slow the progression of metastatic castration-resistant prostate cancer (mCRPC).

How to Use This Medication?

Take this medicine by mouth once a day, 2 hours before or 1 hour after a meal. Swallow the tablets whole without chewing or crushing to avoid further adverse effects.

The dose is based on your medical condition, laboratory results, response to treatment, and any other medicines you are taking. Make sure your doctor and pharmacist know about all the products you are using.

For maximum benefit, take this medicine daily at the same time each day. Do not stop taking your prostate cancer medication unless your doctor tells you to, as stopping treatment may allow the cancer to grow faster.

Possible Side Effects

• Swelling
• Hypokalemia (low potassium)
• Hypertension (high blood pressure)
• Elevated liver enzymes
• Fatigue
• Joint pain
• Nausea
• Vomiting
• Anemia
• Diarrhea

Safety Advise

🩺 Kidney

Caution should be exercised when prescribing Abirapro 250mg Tablets to patients with severe renal disease. Dosage adjustments may be required. Please talk to your healthcare provider.

⚠️ Liver

Abirapro 250mg Tablets should be used cautiously in patients with severe liver disease. Dose adjustment may be necessary. Please discuss with your healthcare provider.

🤰 Pregnancy

Pregnant women should not use Abirapro Tablets as they may cause harm to the foetus. Please talk to your doctor.

🤱 Breastfeeding

Abirapro 250mg Tablet is not recommended during breastfeeding. There is evidence that the medicine may be harmful. Please talk to your healthcare provider.

🍷 Alcohol

It is not known whether it is safe to consume alcohol while taking Abirapro 250mg Tablets. Please consult your healthcare provider.

Storage Instructions

Store in a cool, dry place below 30°C and protect from moisture.

References

• Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.
• Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill.
• Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology. 2008;26(28):4563-4571.
• Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The Oncologist. 2014;19(12):1231-1240.
• Janssen Biotech, Inc. Zytiga (Abiraterone Acetate) Tablets Prescribing Information. U.S. Food and Drug Administration.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.